These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 24743514)

  • 1. Bioactivation of the human carcinogen aristolochic acid.
    Sidorenko VS; Attaluri S; Zaitseva I; Iden CR; Dickman KG; Johnson F; Grollman AP
    Carcinogenesis; 2014 Aug; 35(8):1814-22. PubMed ID: 24743514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioactivation mechanisms of N-hydroxyaristolactams: Nitroreduction metabolites of aristolochic acids.
    Okuno Y; Bonala R; Attaluri S; Johnson F; Grollman AP; Sidorenko VS; Oda Y
    Environ Mol Mutagen; 2019 Dec; 60(9):792-806. PubMed ID: 31374128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of activation of aristolochic acid I and II with NADPH:quinone oxidoreductase, sulphotransferases and N-acetyltranferases.
    Martinek V; Kubickova B; Arlt VM; Frei E; Schmeiser HH; Hudecek J; Stiborova M
    Neuro Endocrinol Lett; 2011; 32 Suppl 1():57-70. PubMed ID: 22167209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulfotransferase-1A1-dependent bioactivation of aristolochic acid I and N-hydroxyaristolactam I in human cells.
    Hashimoto K; Zaitseva IN; Bonala R; Attaluri S; Ozga K; Iden CR; Johnson F; Moriya M; Grollman AP; Sidorenko VS
    Carcinogenesis; 2016 Jul; 37(7):647-655. PubMed ID: 27207664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The human carcinogen aristolochic acid i is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases.
    Stiborová M; Mareš J; Frei E; Arlt VM; Martínek V; Schmeiser HH
    Environ Mol Mutagen; 2011 Jul; 52(6):448-59. PubMed ID: 21370283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of genetic modulation of SULT1A enzymes on DNA adduct formation by aristolochic acids and 3-nitrobenzanthrone.
    Arlt VM; Meinl W; Florian S; Nagy E; Barta F; Thomann M; Mrizova I; Krais AM; Liu M; Richards M; Mirza A; Kopka K; Phillips DH; Glatt H; Stiborova M; Schmeiser HH
    Arch Toxicol; 2017 Apr; 91(4):1957-1975. PubMed ID: 27557898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase.
    Stiborová M; Frei E; Sopko B; Sopková K; Marková V; Lanková M; Kumstýrová T; Wiessler M; Schmeiser HH
    Carcinogenesis; 2003 Oct; 24(10):1695-703. PubMed ID: 12869422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy.
    Stiborová M; Frei E; Sopko B; Wiessler M; Schmeiser HH
    Carcinogenesis; 2002 Apr; 23(4):617-25. PubMed ID: 11960915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols.
    Arlt VM; Stiborova M; Henderson CJ; Osborne MR; Bieler CA; Frei E; Martinek V; Sopko B; Wolf CR; Schmeiser HH; Phillips DH
    Cancer Res; 2005 Apr; 65(7):2644-52. PubMed ID: 15805261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of dicoumarol on the bioactivation of the carcinogen aristolochic acid I in rats.
    Stiborová M; Levová K; Bárta F; Šulc M; Frei E; Arlt VM; Schmeiser HH
    Mutagenesis; 2014 May; 29(3):189-200. PubMed ID: 24598128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of aristolochic acid I on expression of NAD(P)H:quinone oxidoreductase in mice and rats--a comparative study.
    Bárta F; Levová K; Frei E; Schmeiser HH; Arlt VM; Stiborová M
    Mutat Res Genet Toxicol Environ Mutagen; 2014 Jul; 768():1-7. PubMed ID: 24769487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NAD(P)H:quinone oxidoreductase expression in Cyp1a-knockout and CYP1A-humanized mouse lines and its effect on bioactivation of the carcinogen aristolochic acid I.
    Levova K; Moserova M; Nebert DW; Phillips DH; Frei E; Schmeiser HH; Arlt VM; Stiborova M
    Toxicol Appl Pharmacol; 2012 Dec; 265(3):360-7. PubMed ID: 22982977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human sulphotransferases are involved in the activation of aristolochic acids and are expressed in renal target tissue.
    Meinl W; Pabel U; Osterloh-Quiroz M; Hengstler JG; Glatt H
    Int J Cancer; 2006 Mar; 118(5):1090-7. PubMed ID: 16161050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Acetyltransferase and sulfotransferase activity in human prostate: potential for carcinogen activation.
    Al-Buheissi SZ; Patel HR; Meinl W; Hewer A; Bryan RL; Glatt H; Miller RA; Phillips DH
    Pharmacogenet Genomics; 2006 Jun; 16(6):391-9. PubMed ID: 16708048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Aristolochic acid I derived DNA adduct levels in human renal toxicity models.
    Bastek H; Zubel T; Stemmer K; Mangerich A; Beneke S; Dietrich DR
    Toxicology; 2019 May; 420():29-38. PubMed ID: 30940547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers.
    Stiborova M; Frei E; Arlt VM; Schmeiser HH
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):5-11. PubMed ID: 19365519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of 3-nitrobenzanthrone and its metabolites by human acetyltransferases, sulfotransferases and cytochrome P450 expressed in Chinese hamster V79 cells.
    Arlt VM; Glatt H; Muckel E; Pabel U; Sorg BL; Seidel A; Frank H; Schmeiser HH; Phillips DH
    Int J Cancer; 2003 Jul; 105(5):583-92. PubMed ID: 12740904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity.
    Chang SY; Weber EJ; Sidorenko VS; Chapron A; Yeung CK; Gao C; Mao Q; Shen D; Wang J; Rosenquist TA; Dickman KG; Neumann T; Grollman AP; Kelly EJ; Himmelfarb J; Eaton DL
    JCI Insight; 2017 Nov; 2(22):. PubMed ID: 29202460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of p53 on aristolochic acid I-induced nephrotoxicity and DNA damage in vivo and in vitro.
    Sborchia M; De Prez EG; Antoine MH; Bienfait L; Indra R; Valbuena G; Phillips DH; Nortier JL; Stiborová M; Keun HC; Arlt VM
    Arch Toxicol; 2019 Nov; 93(11):3345-3366. PubMed ID: 31602497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of ochratoxin A on DNA adduct formation by the carcinogen aristolochic acid in rats.
    Stiborová M; Bárta F; Levová K; Hodek P; Frei E; Arlt VM; Schmeiser HH
    Arch Toxicol; 2015 Nov; 89(11):2141-58. PubMed ID: 25209566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.